Dehydroepiandrosterone (DHEA) in Aging, Disease Modification, and Symptom Control

REFERENCES

• Regelson W, Loria R, Kalimi M. Hormonal intervention: “buffer hormones” or “state dependency.” The role of dehydroepiandrosterone (DHEA), thyroid hormone, estrogen and hypophysectomy in aging. Ann NY Acad Sci 1988; 521: 260–73
   PubMedGoogle Scholar
• Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA)—the “mother steroid” 1. Immunologic action. Ann NY Acad Sci 1995; 774: 553–63
   Google Scholar
• Loria R M, Regelson W, Padget D A. Immune response facilitation and resistance to viral and bacterial infections with DHEA. The Biologic Role of Dehydroepiandrosterone (DHEA)., M Kalimi, W Regelson. Walter de Gruyter;, New York 1990; 107–130
   Google Scholar
• Loria R M, Inge T H, Cook S, Szakal A, Regelson W. Protection against lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 1988; 26: 301–14
   PubMed Web of Science ®Google Scholar
• Littley M D, Pollock A, Kane J, Shalet S M. Basal serum dehydroepiandrosterone sulfate concentration predicts the cortisol response to provocative testing. Ann Clin Biochem 1990; 27: 537–61
   Google Scholar
• Migeon C J, Plager J E. Identification and isolation of dehydroisoandrosterone from peripheral human plasma. J Biol Chem 1954; 209: 767–72
   PubMed Web of Science ®Google Scholar
• Zumoff B R, Rosenfeld R S, Strain G W, Levin J, Fukushima D K. Sex differences in the twenty-four hour mean plasma concentrations of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) and the DHEA to DHEAS ratio in normal adults. J Clin Endrocinol Metab 1980; 51: 330–33
   PubMed Web of Science ®Google Scholar
• Birkenhager-Gillesse E G, Derksen J, Lagaay A M. Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann NY Acad Sci 1995; 774: 543–52
   Google Scholar
• Watson R R, Huls A, Araghinikuam M, Chung S. Dehydroepiandrosterone and diseases of aging. Drugs, & Aging 1996; 9(4)274–91
   Google Scholar
• Vermeulen A. Adrenal androgens and aging. In:. Adrenal Androgens., A R Genazzani, J HH Thijssen, P K Siiteri. Raven Press;, New York 1980; 207–17
   Google Scholar
• Migeon C J, Keller A R, Lawrence B, Shepard T H. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex day-to-day and diurnal variations. J Clin Endocrinol Metab 1957; 17: 1051–62
   PubMed Web of Science ®Google Scholar
• Longcope C. Metabolism of dehydroepiandrosterone. Ann NY Acad Sci 1995; 774: 143–48
   PubMed Web of Science ®Google Scholar
• Baulieu E E. Dehydroepiandrosterone (DHEA): a fountain of youth?. J Clin Endrocinol Metab 1996; 81: 3147–51
   PubMed Web of Science ®Google Scholar
• De Peretti E, Forest M G. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endrocrinol Metab 1978; 47(3)572–77
   PubMedGoogle Scholar
• Orentreich N, Blind J L, Rizer R L, Vogelman J H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551–55
   PubMed Web of Science ®Google Scholar
• Ohashi M, Fujio N, Kato K, Nawata H, Ibayashi H. Aging is without effect on the pituitary-adrenal axis in men. Gerontology 1986; 32: 335–39
   Google Scholar
• Regelson W, Kalimi M. Dehydroepiandroserone (DHEA)-the multifunctional steroid: Il. Effects on the cns, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action?. Ann NY Acad Sci 1995; 774: 564–75
   Google Scholar
• Nestler J E. DHEA: A coming of age. Ann NY Acad Sci 1995; 774, ix-xi
   Google Scholar
• Yen S SC, Morales A J, Khorram O. Replacement of DHEA in aging men and women. Ann NY Acad Sci 1995; 774: 128–42
   PubMed Web of Science ®Google Scholar
• Morales A J, Nolan J J, Nelson J C, Yen S SC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–67
   PubMed Web of Science ®Google Scholar
• Sunderland T C, Merrill C R, Harrington M G, Lawlor B A, Molchan S E, Martinez R, et al. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet 1989, Sept 2: 570
   Google Scholar
• Spath-Schwalbe E, Dodt C, Dittmann J, Schuttler R, Fehm H L. Dehydroepiandrosterone sulphate in Alzheimer's disease. Lancet 1990; 335: 1412
   Google Scholar
• Leblhuber F, Windhager E, Reisecker F, Steinparz F X, Dienstl E. Dehydroepiandrosterone sulphate in Alzheimer's disease. Lancet 1990; 336: 449
   Google Scholar
• Cuckle H, Stone R, Smith D, Wald N, Brammer M, Hajimohammedreza I, et al. Dehydroepiandrosterone sulphate in Alzheimer's disease. Lancet 1990; 336: 449–50
   Google Scholar
• Schneider L S, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in Alzheimer's disease. Biol Psychiatry 1992; 31: 205–8
   PubMedGoogle Scholar
• Regelson W, Kalimi M, Loria R. DHEA: some thoughts as to its biologic and clinical action. The Biologic Role of Dehydroepiandrosterone (DHEA), M Kalimi, W Regelson. Walter de Gruyter;, New York 1990; 405–45
   Google Scholar
• Wolkowitz O M, Reus V I, Roberts E, Manfredi F, Chan T, Ormiston S, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann NY Acad Sci 1995; 774: 337–9
   PubMedGoogle Scholar
• Barrett-Connor E, Khaw K T. The epidemiology of DHEAS with particular reference to cardiovascular disease: The Rancho Bernardo study. The Biologic Role of Dehydroepiandrosterone (DHEA)., M Kalimi, W Regelson. Walter de Gruyter;, New York 1990; 281–98
   Google Scholar
• Barrett-Connor E, Khaw K T, Yen S SC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 1986; 315: 1519–24
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw K T. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987; 317: 711
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 1995; 774: 259–70
   PubMed Web of Science ®Google Scholar
• Mitchell L E, Sprecher D L, Borecki I B, Rice T, Laskarzewski P M, Rao D C. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 1994; 89: 89–93
   PubMed Web of Science ®Google Scholar
• Herrington D M, Gordon G B, Achuff S C, Trejo J F, Weisman H F, Pearson T A. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990; 16: 862–70
   PubMedGoogle Scholar
• Herrington D M. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci 1995; 774: 271–80
   PubMed Web of Science ®Google Scholar
• Newcomer L M, Manson J E, Barbieri R L, Hennekens C H, Stampfer M J. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: A prospective study. Am J Epidemiol 1994; 140: 870–5
   Google Scholar
• Daynes R A, Araneo B A, Ershler W B, Maloney C, Li G, Ryu S. Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993; 150: 5219–30
   PubMed Web of Science ®Google Scholar
• Malone J, Oldfield Ill E G, Wagner K F, Simms T E, Daly R, O'Brian J, et al. Abnormalities of morning serum cortisol levels and circadian rhythms of CD4+ lymphocyte counts in human immunodeficiency virus type 1 infected adult patients. J Infect Dis 1992; 165: 185–6
   Google Scholar
• Alak J IB, Shahbazian M, Huang D S, Wang Y, Darban H, Jenkins E M, et al. Alcohol and murine acquired immunodeficiency syndrome suppression of resistance to Cryptosporidium parvum infection during modulation of cytokine production. Alcohol Clin Exp Res 1993; 17: 539–44
   Google Scholar
• Merrill C R, Harrison M G, Sunderland T. Plasma dehydroepiandrosterone levels in HIV infection. JAMA 1989; 261: 1149
   Google Scholar
• Chehimi J, Starr S E, Frank L, D'Andrea A, Xiaojing M, MacGregor R R, et al. Impaired interleukin-12 production in human immunodeficiency virus-infected patients. J Exp Med 1994; 179: 1361–6
   PubMed Web of Science ®Google Scholar
• Clerici M, Wynn T A, Berzofsky J A, Blatt S P, Hendrix G W, Sher A, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93: 768–75
   PubMed Web of Science ®Google Scholar
• Kovacs J A, Baseler M, Dewer R, Vogel S, Davey R T, Falloon J, et al. Increases in the CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567–75
   PubMed Web of Science ®Google Scholar
• Daynes R A, Dudley D J, Araneo B A. Regulation of murine lymphokine production in vivo. Eur J Immunol 1990; 20: 793–802
   PubMed Web of Science ®Google Scholar
• Wichmann U, Wichmann G, Krause W. Serum levels of testosterone precursors, testosterone and estradiol in animal species. Exp Clin Endocrinol 1984; 83: 283–90
   PubMedGoogle Scholar
• Jacobson M A, Fusaro R E, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200–499. J Infect Dis 1991; 164: 864–8
   PubMed Web of Science ®Google Scholar
• Goedart J J, Kessler C M, Aledort L M. A prospective study of human immunodeficiency virus type I infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141–8
   Google Scholar
• Mulder J W, Frissen J, Krijen X, Endert E, Wolf F, Goudsmit J, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992; 165: 413–8
   PubMed Web of Science ®Google Scholar
• Dyner T S, Lang W, Geaga J, Golub A, Stites D, Winger E, et al. An open-label dose escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Synd 1993; 6: 459–65
   PubMed Web of Science ®Google Scholar
• Rodriguez M. Multiple sclerosis. Basic concepts and hypothesis. Mayo Clin Proc 1989; 64: 570–6
   PubMed Web of Science ®Google Scholar
• Steinberg A D, Gourley M F, Klinman D M, Tsokos G C, Scott D E, Krieg A M. Systemic lupus erythematosus. Ann Intern Med 1991; 115: 548–59
   PubMed Web of Science ®Google Scholar
• Roberts E, Fauble T J. Oral dehydroepiandrosterone in multiple sclerosis. Results of a phase I, open study. The Biologic Role of Dehydroepiandrosterone., M Kalimi, W Regelson. Walter de Gruyter;, New York 1990; 81–91
   Google Scholar
• Calabrese V P, Isaacs E R, Regelson W R. Dehydroepiandrosterone in multiple sclerosis: Positive effects on the fatigue syndrome in a non-randomized study. The Biologic Role of Dehydroepiandrosterone., M Kalimi, W Regelson. Walter de Gruyter;, New York 1990; 95–100
   Google Scholar
• Lahita R G, Bradlow H L, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241–8
   PubMed Web of Science ®Google Scholar
• Lucas J A, Ahmed S A, Casey M L, MacDonald P C. J Clin Invest 1985; 75: 2091–9, Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice fed dehydroepiandrosterone.;
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven R F, Engleman E G, McGuire J L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1305–10
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven R F, Engleman E G, McGuire J L. Dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1826–31
   PubMed Web of Science ®Google Scholar
• Bulbrook R D, Hayward J L, Spicer C C. Relation between urinary androgen and corticosteroid excretion and subsequent breast cancer. Lancet 1971; 2: 395–8
   PubMed Web of Science ®Google Scholar
• Zumoff B, Levin J, Rosenfeld R S, Markham M, Strain G W, Fukushima D K. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981; 41: 3360–3
   PubMed Web of Science ®Google Scholar
• Helzlsouer K J, Gordon G B, Alberg A J, Bush T L, Comstock G W. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992; 52: 1–4
   PubMed Web of Science ®Google Scholar
• Gordon G B, Bush T L, Helzlsouer K J, Miller S R, Comstock G W. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990; 50: 3859–62
   Google Scholar
• Barrett-Connor E, Friedlander N, Khaw K. Cancer Res 1990; 50: 6571–4, T: Dehydroepiandrosterone sulfate and breast cancer risk.;
   PubMed Web of Science ®Google Scholar
• Helzlsouer K J, Alberg A J, Gordon G B, Longcope C, Bush T L, Hoffman S C, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 274: 1926–30
   PubMed Web of Science ®Google Scholar
• Gordon G B, Helzlsouer K J, Alberg A J, Comstock G W. Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 33–5
   PubMedGoogle Scholar
• Gordon G B, Helzlsouer K J, Comstock G W. Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 1991; 51: 1366–9
   PubMedGoogle Scholar
• Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807–11
   PubMed Web of Science ®Google Scholar
• Nestler J E. Regulation of human dehydroepiandrosterone metabolism by insulin. Ann NY Acad Sci 1995; 774: 73–81
   PubMed Web of Science ®Google Scholar
• Buffington C K, Pourmotabbed G, Kitabchi A E. Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 1993; 306: 320–4
   PubMedGoogle Scholar
• Nestler J E, Beer N A, Jakubowicz D J, Colombo C, Beer R M. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA-sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab 1995; 80: 700–6
   PubMed Web of Science ®Google Scholar
• Nestler J E, Clore J N, Strauss Ill J F, Blackard W G. J Clin Endocrinol Metab 1987; 64: 180–4, The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans.;
   PubMed Web of Science ®Google Scholar
• Nestler J E, Usiskin K S, Barlascini C O, Welty D F, Clore J N, Blackard W G. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab 1989; 69: 1040–6
   PubMed Web of Science ®Google Scholar
• Bates G W, Egerman R S, Umstot E S, Buster J E, Casson P R. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in post-menopausal women. Ann NY Acad Sci 1995; 774: 291–3
   Google Scholar
• Mortola J F, Yen S SC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696–704
   PubMed Web of Science ®Google Scholar
• Nestler J E, Clore J N, Blackard W G. Dehydroepiandrosterone: the “missing link” between hyperinsulinemia and atherosclerosis?. FASEB J 1992; 6: 3073–5
   PubMedGoogle Scholar
• Grady D, Rubin S M, Petitti D B, Fox C S, Black D B, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37
   PubMed Web of Science ®Google Scholar
• Taclman P, Kaufman J M, Janssens X, Vermeulen A. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause. Maturitas 1989; 11: 65–73
   Google Scholar
• Wild R A, Buchanan J R, Myers C, Demers L M. Declining adrenal androgens: An association with bone loss in aging women. Proc Soc Exp Biot Med 1987; 186: 355–60
   Google Scholar
• Spector T D, Thompson P W, Perry L A, McGarrigle H H, Edwards A C. The relationship between sex steroids and bone mineral content in women soon after the menopause. Clin Endocrinol 1991; 34: 37–41
   Google Scholar
• Devogelaer J P, Crabbc J, De Deuxchaisnes C N. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J 1987; 294: 798–800
   PubMed Web of Science ®Google Scholar
• Nawata J, Tanaka S, Tanaka S, Takayanagi R, Sakai Y, Yanase T, et al. Aromatase in bone cell: Association with osteoporosis in postmenopausal women. J Steroid Biochem Molec Biol 1995; 53: 165–74
   PubMed Web of Science ®Google Scholar
• Mohan P F, Ihnen J S, Levin B E, Cleary M P. Effects of dehydroepiandrosterone treatment in rats with diet induced obesity. J Nutr 1990; 120: 1103–14
   PubMed Web of Science ®Google Scholar
• MacEwan E G, Kurzman I D, Haffa A LM. Antiobesity and hypocholesterolemic activity of dehydroepiandrosterone (DHEA) in the dog. Hormones Thermogenesis and Obesity, H Lardy, F Stratman. Elsevier Science Publishing;, New York 1989; 399–404
   Google Scholar
• Usiskin K S, Butterworth S, Clore J N, Arad Y, Ginsberg H N, Blackard W G, et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obesity 1990; 14: 457–63
   PubMed Web of Science ®Google Scholar
• Araneo B, Dowell T, Woods T, Daynes R, Judd M, Evans T. DHEAS as an effective vaccine adjuvant in elderly humans: Proof-of-principle studies. NY Acad Sci 1995; 774: 232–48
   Google Scholar
• Buster J E, Casson P R, Straughn A B, Dale D, Umstot E S, Chiamori N, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol 1992; 166: 1163–8
   PubMed Web of Science ®Google Scholar
• Araghiniknam M, Chung S, Nelson-White T, Eskelson C, Watson R R. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci 1996; 59: 147–57
   Web of Science ®Google Scholar
• Skolnick A A. Scientific verdict still out on DHEA. JAMA 1996; 276: 1365–7
   PubMed Web of Science ®Google Scholar
• Baulieu E E. Dehydroepiandrosterone (DHEA): A fountain of youth?. J Clin Endocrinol Metab 1996; 81: 3147–51
   PubMed Web of Science ®Google Scholar
• Hornsby P J. Current challenges for DHEA research. Ann NY Acad Sci 1995; 774, xiii-xiv
   Google Scholar
• NDA Pipeline 1996. FDC Report Inc. Chevy Chase, Maryland 1997; 15: 318, Volume: 274, 692, 715, 716
   Google Scholar